Real data comparison
Tencent: Hy4 preview vs NVIDIA: Nemotron 3 Ultra (free)
On price, NVIDIA: Nemotron 3 Ultra (free) is cheaper ($1.25 vs $1.25 per 1M). In real production usage, Tencent: Hy4 preview is used more (rank #3 vs #11 of 325). Across 6 real task categories where both models have classified traffic, Tencent: Hy4 preview handles more of the traffic in 4 of them.
- Tencent: Hy4 preview
- NVIDIA: Nemotron 3 Ultra (free)
Head-to-head by real task
Tencent: Hy4 preview leads 4 of 6 shared task categories by real classified traffic share; NVIDIA: Nemotron 3 Ultra (free) leads 2. Not a benchmark score - this is what developers actually route to each model for, per OpenRouter's task classification.
| Task | Tencent: Hy4 preview | NVIDIA: Nemotron 3 Ultra (free) |
|---|---|---|
| Repo Scanning | 4.0% | 3.0% |
| Frontend & UI | 4.5% | 3.7% |
| DevOps & Config | 2.1% | 2.8% |
| SQL & Database | 3.2% | 2.9% |
| Shell Execution | 3.1% | 2.8% |
| Debugging | 2.7% | 2.8% |
Usage share over time
- Tencent: Hy4 preview
- NVIDIA: Nemotron 3 Ultra (free)
Frequently asked questions
Tencent: Hy4 preview vs NVIDIA: Nemotron 3 Ultra (free): which is better quality?
Quality data is unavailable for one or both models.
Tencent: Hy4 preview vs NVIDIA: Nemotron 3 Ultra (free): which is cheaper?
NVIDIA: Nemotron 3 Ultra (free) is cheaper at $1.25/1M vs $1.25/1M.
Tencent: Hy4 preview vs NVIDIA: Nemotron 3 Ultra (free): which is used more?
Tencent: Hy4 preview has higher real OpenRouter usage share (rank #3 vs #11 of 325).
Tencent: Hy4 preview vs NVIDIA: Nemotron 3 Ultra (free): which wins more real-world task categories?
Tencent: Hy4 preview handles more traffic in 4 of 6 shared task categories where both models have classified OpenRouter usage.
Source: OpenRouter (openrouter.ai/rankings), as of September 9, 2026.
Benchmark scores: Artificial Analysis (artificialanalysis.ai) via OpenRouter (openrouter.ai/rankings).
Methodology: www.smophy.ai/benchmark/methodology
Token counts originate from each provider's own tokenizer and are not directly comparable across providers.